将肿瘤不断变化的分子谱转化为癌症免疫治疗的反应生物标志物。
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.
机构信息
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
出版信息
Sci Transl Med. 2022 Nov 9;14(670):eabo3958. doi: 10.1126/scitranslmed.abo3958.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering studies to understand the molecular and cellular wiring of response and resistance. Our increased understanding of the underlying biology of response to ICI has enabled the investigation of tumor-intrinsic and -extrinsic features that may predict therapeutic outcomes. In parallel, liquid biopsy measurements of circulating tumor DNA (ctDNA) can be used to assess real-time molecular responses and guide clinical decisions during ICI. The combination of these approaches provides a deeper understanding of cancer biology, immunoediting, and evolution during ICI and promise to extend the utility of immunotherapies for patients with cancer.
摘要
免疫检查点抑制剂（ICIs）彻底改变了癌症治疗方法，引发了一系列研究，旨在深入了解其作用机制和耐药机制。我们对 ICI 应答相关的分子和细胞机制的理解不断加深，这有助于探索可能预测治疗效果的肿瘤内在和外在特征。与此同时，通过液体活检测量循环肿瘤 DNA（ctDNA）可以实时评估分子应答情况，并指导 ICI 期间的临床决策。这些方法的结合提供了对 ICI 期间癌症生物学、免疫编辑和进化的更深入了解，并有望为癌症患者提供更广泛的免疫治疗选择。
相似文献
1
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.将肿瘤不断变化的分子谱转化为癌症免疫治疗的反应生物标志物。
Sci Transl Med. 2022 Nov 9;14(670):eabo3958. doi: 10.1126/scitranslmed.abo3958.
2
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.液体活检在癌症免疫治疗中捕获肿瘤演变和临床结果的方法。
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-005924.
3
Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.循环肿瘤 DNA 在 PD-1/PD-L1 免疫检查点抑制剂中的作用：当前证据和未来方向。
Int Immunopharmacol. 2022 Oct;111:109173. doi: 10.1016/j.intimp.2022.109173. Epub 2022 Aug 20.
4
Use of Circulating Tumor DNA for Cancer Immunotherapy.循环肿瘤 DNA 在癌症免疫治疗中的应用。
Clin Cancer Res. 2019 Dec 1;25(23):6909-6915. doi: 10.1158/1078-0432.CCR-18-2688. Epub 2019 Jul 8.
5
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.早期治疗时循环肿瘤 DNA 测量与晚期尿路上皮癌免疫检查点抑制剂反应的关系。
Eur Urol Oncol. 2024 Apr;7(2):282-291. doi: 10.1016/j.euo.2023.08.009. Epub 2023 Sep 4.
6
Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.黑色素瘤免疫检查点阻断治疗期间循环肿瘤 DNA 的克隆动力学。
Cancer Sci. 2021 Nov;112(11):4748-4757. doi: 10.1111/cas.15088. Epub 2021 Sep 22.
7
Genetic profiling of cancer with circulating tumor DNA analysis.利用循环肿瘤 DNA 分析进行癌症的基因谱分析。
J Genet Genomics. 2018 Feb 20;45(2):79-85. doi: 10.1016/j.jgg.2017.11.006. Epub 2018 Feb 5.
8
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.循环肿瘤 DNA 作为生物标志物，用于监测接受免疫检查点抑制剂治疗的晚期肺腺癌患者的早期治疗反应。
Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25.
9
Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.个体化循环肿瘤 DNA 检测监测免疫治疗疗效和预测局部晚期或转移性非小细胞肺癌的结局。
Cancer Med. 2023 Jul;12(13):14317-14326. doi: 10.1002/cam4.6108. Epub 2023 May 15.
10
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.外周血免疫细胞动态变化反映抗肿瘤免疫反应，并预测免疫治疗的临床反应。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004688.
引用本文的文献
1
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.帕博利珠单抗与放疗联合可在免疫冷型非小细胞肺癌中诱导全身抗肿瘤免疫反应。
Nat Cancer. 2025 Jul 22. doi: 10.1038/s43018-025-01018-w.
2
Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.代谢和营养紊乱对非小细胞肺癌放疗与免疫治疗协同作用的影响。
BMC Cancer. 2025 May 27;25(1):948. doi: 10.1186/s12885-025-14278-7.
3
Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.论背景、质量与复杂性：梳理免疫治疗癌症中的肿瘤突变负荷
Clin Cancer Res. 2025 Jul 15;31(14):2850-2863. doi: 10.1158/1078-0432.CCR-23-0824.
4
Discovery of a DNA repair-associated radiosensitivity index for predicting radiotherapy efficacy in breast cancer.发现一种与DNA修复相关的放射敏感性指数用于预测乳腺癌放疗疗效
Front Oncol. 2025 Mar 25;15:1439516. doi: 10.3389/fonc.2025.1439516. eCollection 2025.
5
Overview on biomarkers for immune oncology drugs.免疫肿瘤学药物生物标志物概述。
Explor Target Antitumor Ther. 2025 Mar 17;6:1002298. doi: 10.37349/etat.2025.1002298. eCollection 2025.
6
Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy.借助人工智能拉曼光谱推进精准癌症免疫治疗药物的开发、给药及反应预测。
Front Immunol. 2025 Jan 9;15:1520860. doi: 10.3389/fimmu.2024.1520860. eCollection 2024.
7
Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes.定量外周血活单个T细胞动态多功能分析可预测肺癌检查点免疫治疗的疗效和临床结局。
Transl Lung Cancer Res. 2024 Dec 31;13(12):3323-3343. doi: 10.21037/tlcr-24-260. Epub 2024 Dec 17.
8
Novel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment.剖析肺癌免疫微环境的新型空间方法
Cancers (Basel). 2024 Dec 12;16(24):4145. doi: 10.3390/cancers16244145.
9
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432).免疫检查点抑制持久临床获益的非侵入性早期识别：一项前瞻性多中心研究（NCT04566432）
Signal Transduct Target Ther. 2024 Dec 16;9(1):350. doi: 10.1038/s41392-024-02060-3.
10
Local Exosome Inhibition Potentiates Mild Photothermal Immunotherapy Against Breast Cancer.局部外泌体抑制增强对乳腺癌的温和光热免疫疗法
Adv Sci (Weinh). 2025 Jan;12(2):e2406328. doi: 10.1002/advs.202406328. Epub 2024 Nov 22.
本文引用的文献
1
The status of tumor mutational burden and immunotherapy.肿瘤突变负荷与免疫治疗的现状。
Nat Cancer. 2022 Jun;3(6):652-656. doi: 10.1038/s43018-022-00382-1.
2
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.帕博利珠单抗治疗微卫星高度不稳定或错配修复缺陷型癌症：来自 II 期 KEYNOTE-158 研究的更新分析。
Ann Oncol. 2022 Sep;33(9):929-938. doi: 10.1016/j.annonc.2022.05.519. Epub 2022 Jun 6.
3
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.PD-1 阻断在错配修复缺陷、局部晚期直肠癌中的应用。
N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5.
4
Automated next-generation profiling of genomic alterations in human cancers.自动化的人类癌症基因组改变的下一代测序分析。
Nat Commun. 2022 May 20;13(1):2830. doi: 10.1038/s41467-022-30380-x.
5
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer.新抗原质量可预测胰腺癌幸存者的免疫编辑。
Nature. 2022 Jun;606(7913):389-395. doi: 10.1038/s41586-022-04735-9. Epub 2022 May 19.
6
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌，2022年第3版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025.
7
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.突变 PIK3CA 衍生的公共新抗原的免疫原性和治疗靶向。
Nat Med. 2022 May;28(5):946-957. doi: 10.1038/s41591-022-01786-3. Epub 2022 Apr 28.
8
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.基于血液的肿瘤突变负担作为非小细胞肺癌中阿替利珠单抗的生物标志物：B-F1RST 期 2 试验。
Nat Med. 2022 May;28(5):939-945. doi: 10.1038/s41591-022-01754-x. Epub 2022 Apr 14.
9
Cancer germline antigens and tumor-agnostic CD8 T cell evasion.癌症种系抗原与肿瘤非特异性CD8 T细胞逃逸
Trends Immunol. 2022 May;43(5):391-403. doi: 10.1016/j.it.2022.03.006. Epub 2022 Apr 10.
10
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
Zotero 插件